{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:13:05Z","timestamp":1785870785843,"version":"3.56.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.dld.2026.02.014","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T21:33:52Z","timestamp":1774042432000},"page":"599-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD\/MASH): A 2026 Update"],"prefix":"10.1016","volume":"58","author":[{"given":"Alessio","family":"Aghemo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Armandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0946-3859","authenticated-orcid":false,"given":"Giuseppe","family":"Cabibbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-1153","authenticated-orcid":false,"given":"Roberta","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0402-4176","authenticated-orcid":false,"given":"Andrea","family":"Dalbeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6414-4404","authenticated-orcid":false,"given":"Simone","family":"Di Cola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Germani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3493-6504","authenticated-orcid":false,"given":"Massimo","family":"Iavarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8629-0878","authenticated-orcid":false,"given":"Fabio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0550-8201","authenticated-orcid":false,"given":"Mario","family":"Masarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-3948","authenticated-orcid":false,"given":"Giuseppe","family":"Marrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Miele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Pennisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Petta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Ponziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1142-8585","authenticated-orcid":false,"given":"Federico","family":"Ravaioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-1155","authenticated-orcid":false,"given":"Francesco","family":"Tovoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-0345","authenticated-orcid":false,"given":"Luca","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vespasiani-Gentilucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Vigano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.02.014_bib0001","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.014_bib0002","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/liv.13743","article-title":"Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population","volume":"38","author":"Petta","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2026.02.014_bib0003","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000087295","article-title":"Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy","volume":"49","author":"Colicchio","year":"2005","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.dld.2026.02.014_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2931985","article-title":"The burden of NAFLD and its characteristics in a nationwide population with type 2 diabetes","volume":"2016","author":"Forlani","year":"2016","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.dld.2026.02.014_bib0005","article-title":"Effectiveness of a model of care based on fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicenter study","volume":"180","author":"Caviglia","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.02.014_bib0006","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00592-012-0406-1","article-title":"Non-alcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian arteriosclerosis society","volume":"50","author":"Soresi","year":"2013","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.dld.2026.02.014_bib0007","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ueg2.12513","article-title":"Predictors of controlled attenuation parameter in metabolic dysfunction","volume":"12","author":"Bianco","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.dld.2026.02.014_bib0008","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diabres.2017.10.023","article-title":"Trend over time in hepatic fibrosis score in a cohort of type 2 diabetes patients","volume":"135","author":"Giorda","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dld.2026.02.014_bib0009","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.014_bib0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2021-324915","article-title":"Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database","volume":"72","author":"Vitale","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.02.014_bib0011","article-title":"Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: an Italian liver transplant registry study","volume":"6","author":"Vitale","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2026.02.014_sbref0012","series-title":"Food and Drug Administration, Center for Drug Evaluation and Research. Noncirrhotic non-alcoholic steatohepatitis with liver fibrosis: developing drugs for treatment. Guidance for industry [draft guidance]","year":"2018"},{"key":"10.1016\/j.dld.2026.02.014_bib0013","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.31296","article-title":"Thyroid hormone signaling and the liver","volume":"72","author":"Ritter","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.014_bib0014","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicenter, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.02.014_bib0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.dld.2026.02.014_bib0016","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.014_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70407","article-title":"Focus on Semaglutide 2,4 mg\/week for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"45","author":"Petta","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2026.02.014_bib0018","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.dld.2026.02.014_bib0019","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 deacreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.02.014_bib0020","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicenter, double-blind, randomized, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.02.014_bib0021","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.dld.2026.02.014_bib0022","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.014_bib0023","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13543784.2022.2032640","article-title":"Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials","volume":"31","author":"Aggarwal","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.dld.2026.02.014_bib0024","first-page":"495","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.02.014_bib0025","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.014_bib0026","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD practice guidance","author":"Bansal","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.014_bib0027","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/HEP.0000000000000616","article-title":"Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: a comparative analysis of various risk stratification criteria","volume":"79","author":"Pennisi","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.014_bib0028","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S2468-1253(24)00234-6","article-title":"Spleen stiffness measurement by vibration-controlled transient elastography at 100 hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modeling study","volume":"9","author":"Jachs","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.02.014_bib0029","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1136\/gutjnl-2025-335542","article-title":"Non-invasive tests of fibrosis in the management of MASLD: revolutionizing diagnosis, progression and regression monitoring","volume":"74","author":"Feng","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.02.014_bib0030","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/HEP.0000000000001190","article-title":"Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: a multilevel random effects model meta-analysis","volume":"82","author":"Indre","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.014_bib0031","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/gutjnl-2022-328689","article-title":"Diagnostic accuracy of Fibroscan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"72","author":"Ravaioli","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.02.014_bib0032","unstructured":"https:\/\/www.accessdata.fda.gov\/spl\/data\/742c1e89-4b8e-4048-82c1-df9e43fbc22a\/742c1e89-4b8e-4048-82c1-df9e43fbc22a.xml. (Last access 10th March 2026)."},{"key":"10.1016\/j.dld.2026.02.014_bib0033","unstructured":"https:\/\/www.accessdata.fda.gov\/spl\/data\/6d001eae-d777-46c0-a89b-d55cae3faf7b\/6d001eae-d777-46c0-a89b-d55cae3faf7b.xml. (Last access 10th March 2026)."},{"key":"10.1016\/j.dld.2026.02.014_bib0034","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2024.05.008","article-title":"Increase and decrease in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD","volume":"81","author":"Gawrieh","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.02.014_bib0035","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.cgh.2022.08.036","article-title":"Clinical utility of combined MRI-PDFF and ALT response in predicting histologic response in non-alcoholic fatty liver disease","volume":"21","author":"Huang","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.02.014_bib0036","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.02.014_bib0037","article-title":"Fibroscan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomized, double-blind, placebo-controlled, phase 2b trial","volume":"66","author":"Wong","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.dld.2026.02.014_bib0038","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/gutjnl-2023-331401","article-title":"MASH resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH","volume":"73","author":"Loomba","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.02.014_bib0039","article-title":"Biopsy-free endpoints in MASH trials: a comparative look at MASHResInd and FAST","author":"Ravaioli","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.02.014_bib0040","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.3390\/jcm14113791","article-title":"Weight regain after liraglutide, semaglutide or tirzepatide interruption: a narrative review of randomized studies","volume":"14","author":"Quarenghi","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2026.02.014_bib0041","article-title":"Abdullah Bin Ahmed I. A comprehensive review on weight gain following discontinuation of glucagon-like peptide-1 receptor agonists for obesity","volume":"2024","year":"2024","journal-title":"J Obes"},{"key":"10.1016\/j.dld.2026.02.014_bib0042","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.014_bib0043","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.014_bib0044","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13668-025-00649-w","article-title":"Impact of GLP-1 Receptor agonist therapy in patients at high risk for sarcopenia","volume":"14","author":"Memel","year":"2025","journal-title":"Curr Nutr Rep"},{"key":"10.1016\/j.dld.2026.02.014_bib0045","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.014_bib0046","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.014_bib0047","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.02.014_bib0048","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.014_bib0049","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.02.014_bib0050","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.02.014_bib0051","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.3390\/jcm13206100","article-title":"Semaglutide treatment effects on liver fat content in obese subjects with metabolic-associated steatotic liver disease (MASLD)","volume":"13","author":"Dusilova","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2026.02.014_bib0052","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0168-8278(24)00599-3","article-title":"Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis \u2013 a subgroup analysis from the SELECT trial","volume":"80","author":"Meyhofer","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.02.014_bib0053","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.014_bib0054","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of non-alcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.dld.2026.02.014_bib0055","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s12072-025-10857-9","article-title":"Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study","volume":"19","author":"Wu","year":"2025","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2026.02.014_bib0056","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/diseases12080186","article-title":"Therapeutic effects of semaglutide on non-alcoholic fatty liver disease with type 2 diabetes mellitus and obesity: an open-label controlled trial","volume":"12","author":"Gad","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.dld.2026.02.014_bib0057","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomized, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.02.014_bib0058","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.02.014_bib0059","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826002926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826002926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:34:50Z","timestamp":1776238490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826002926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1590865826002926"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.02.014","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD\/MASH): A 2026 Update","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}